TECENTRIQ (atezolizumab) recall in Canada: risk of myocarditis
In plain language
This recall involves TECENTRIQ (atezolizumab) concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials. It's being recalled because it may cause severe myocarditis (inflammation of the heart muscle). Patients should contact their healthcare professional if they experience symptoms like chest pain or shortness of breath.
What to do
- Contact your healthcare professional if you are using TECENTRIQ.
- Discuss any questions or concerns with your healthcare professional.
- Report any suspected side effects to Hoffmann-La Roche Limited or Health Canada.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
TECENTRIQ (atezolizumab), concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials
Why this matters
Risk of myocarditis
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of myocarditis
What should consumers do?
Contact your healthcare professional if you are using TECENTRIQ. Discuss any questions or concerns with your healthcare professional. Report any suspected side effects to Hoffmann-La Roche Limited or Health Canada.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of myocarditis
When was this product recalled?
This product was recalled on February 14, 2018.
Is the TECENTRIQ brand affected by this recall?
Yes, TECENTRIQ products are affected by this recall. This recall involves TECENTRIQ (atezolizumab) concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials. It's being recalled because it may cause severe myocarditis (inflammation of the heart muscle). Patients should contact their healthcare professional if they experience symptoms like chest pain or shortness of breath.